IRIS
MAFFIOLI, PAMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.582
AS - Asia 6.341
EU - Europa 4.996
SA - Sud America 954
AF - Africa 100
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.995
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.396
CN - Cina 3.769
SG - Singapore 1.267
IE - Irlanda 1.176
UA - Ucraina 926
BR - Brasile 795
DE - Germania 743
FI - Finlandia 675
HK - Hong Kong 672
RU - Federazione Russa 510
IT - Italia 290
SE - Svezia 269
VN - Vietnam 262
GB - Regno Unito 208
CA - Canada 126
IN - India 66
AR - Argentina 57
FR - Francia 49
BD - Bangladesh 41
MX - Messico 40
EC - Ecuador 38
ZA - Sudafrica 36
ID - Indonesia 32
JP - Giappone 30
TR - Turchia 28
IQ - Iraq 25
NL - Olanda 24
ES - Italia 22
PL - Polonia 21
UZ - Uzbekistan 18
IR - Iran 17
CO - Colombia 16
PE - Perù 16
JO - Giordania 14
BE - Belgio 11
MA - Marocco 11
TH - Thailandia 11
AL - Albania 10
EG - Egitto 10
VE - Venezuela 10
IL - Israele 9
MU - Mauritius 9
RO - Romania 9
AT - Austria 8
DZ - Algeria 8
NZ - Nuova Zelanda 8
PK - Pakistan 8
PY - Paraguay 8
AU - Australia 7
AZ - Azerbaigian 7
CL - Cile 6
KE - Kenya 6
KR - Corea 6
KZ - Kazakistan 6
TN - Tunisia 6
BH - Bahrain 5
JM - Giamaica 5
KG - Kirghizistan 5
MY - Malesia 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
AM - Armenia 4
EE - Estonia 4
GR - Grecia 4
LT - Lituania 4
PA - Panama 4
PH - Filippine 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
LV - Lettonia 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
SA - Arabia Saudita 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
IS - Islanda 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MD - Moldavia 2
NC - Nuova Caledonia 2
NI - Nicaragua 2
TW - Taiwan 2
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
DJ - Gibuti 1
GT - Guatemala 1
Totale 19.977
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.326
Dublin 1.176
Chandler 1.053
Nanjing 1.001
Dallas 687
Hong Kong 672
Singapore 489
Ashburn 475
Boardman 430
Nanchang 421
Beijing 340
Shenyang 300
Hebei 283
Princeton 283
Lawrence 275
Medford 267
Changsha 256
Wilmington 253
Jiaxing 221
Los Angeles 190
Munich 174
Hangzhou 171
Helsinki 155
Tianjin 149
Redondo Beach 123
Buffalo 115
Ho Chi Minh City 100
Moscow 92
São Paulo 79
Toronto 72
Shanghai 57
Cambridge 54
Ann Arbor 53
Milan 51
Seattle 50
Hanoi 49
Woodbridge 49
New York 46
Fairfield 33
Norwalk 33
Turku 31
Jinan 29
Tokyo 29
Johannesburg 24
Montreal 24
Des Moines 23
Guangzhou 23
Kunming 23
Rio de Janeiro 23
San Francisco 23
Brooklyn 22
Santa Clara 22
Zhengzhou 21
Bruino 19
Pavia 19
Belo Horizonte 18
Stockholm 18
Genova 17
Orem 17
Tashkent 17
Boston 16
Campinas 16
Quito 16
The Dalles 16
Chicago 15
London 15
Pune 15
Chennai 14
Warsaw 14
Curitiba 13
Falkenstein 13
Ningbo 13
Orange 13
Phoenix 13
Piscataway 13
Amman 12
Charlotte 12
Haiphong 12
Lima 12
Salvador 12
Bologna 11
Guayaquil 11
Ankara 10
Dhaka 10
Frankfurt am Main 10
Guarulhos 10
Baghdad 9
Brussels 9
Da Nang 9
Eindhoven 9
Mexico City 9
Quận Bình Thạnh 9
Bangkok 8
Bogotá 8
Denver 8
Hải Dương 8
Poplar 8
Secaucus 8
Shijiazhuang 8
West Jordan 8
Totale 13.000
Salva come PNG Salva come JPEG
Nome #
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial 231
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 184
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial 166
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 141
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 136
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 123
Diagnostico y Tratamiento de los desordenes lipidicos. Mc Graw Hill Education 2014. 116
A systematic reviewandmeta-analysis of randomized controlled trials investigating the effects of supplementationwith Nigella sativa (black seed) on blood pressure 115
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 114
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients 112
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 110
Abscisic Acid Treatment in Patients with Prediabetes. 109
Diarrea in paziente diabetico 108
A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus 107
Effetti sulla variabilità glicemica e sul compenso glico-metabolico di metformina, pioglitazone e sitagliptin in pazienti affetti da diabete mellito di tipo 2 107
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients 106
Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study 104
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 104
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 102
A randomized, double blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetic patients already treated with pioglitazone and metformin: a three years study 102
A curious case of hypoglycaemia 101
Confronto tra candesartan e olmesartan sui parametri correlati alla sensibilità insulinica nei pazienti ipertesi con diabete mellito di tipo 2 101
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 100
Acarbose compared to placebo on insulin resistance biomarkers in a double-blind, placebo-controlled trial 100
Adipocytokines levels in obese and non-obese subjects, an observational study 100
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk 100
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load 100
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 99
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 99
A clinical trial about a food supplement containing α-lipoic acid on oxidative stress markers in type 2 diabetic patients 97
Differenti effetti di candesartan e olmesartan sui parametri di attività del tessuto adiposo in pazienti diabetici di tipo 2 ipertesi 95
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study 95
Effetti di un anno di trattamento con vildagliptin associato a pioglitazone o glimepiride in pazienti diabetici scarsamente controllati 92
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 91
Effetti di un anno di trattamento con orlistat+L-carnitina paragonato a orlistat o placebo sui parametri di insulino-resistenza nei pazienti diabetici 91
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 91
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. 91
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. 91
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 90
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 89
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis 89
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus 89
Effects of a combination of Berberis aristata, Silybum marianum and monacolin on lipid profile in subjects at low cardiovascular risk; a double-blind, randomized, placebo-controlled trial 89
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients 88
Effects of sibutramine plus L-carnitine compared to sibutramine on inflammatory parameters in type 2 diabetic patients 88
Effects of berberine on lipid profile in subjects with low cardiovascular risk 86
Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients 85
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus 84
Candesartan effect on inflammation in hypertension 84
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin 83
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 83
Effect of manidipine-rosuvastatin combination on fibrinolysis, inflammation markers and insulin sensitivity in hypertensive hypercholesterolemic patients 83
Valutazione dell’infiammazione e delle MMPs nei soggetti con e senza diabete durante OGTT 82
Prevalence and associations of erectile dysfunction in a sample of italian males with type 2 diabetes. 82
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 81
Aerobic physical activity in obese subjects compared to anaerobic/aerobic physical activity 81
Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. 81
Hypoglycemia, its implications in the clinical practice, and possible ways to prevent it. 80
Berberine induced improvement in hepatic steatosis index in overweight dyslipidaemic patients treated with lipid-lowering nutraceuticals 80
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 78
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 78
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 78
Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: A randomized, double-blind, placebo controlled study 78
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study 77
Anti-obesity drugs: a review about their effects and their safety 77
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 77
Prevalence of erectile dysfunction in males affected by type 2 diabetes and the impact of hyperinsulinemia 77
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study 76
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 76
Metformina in bustine rispetto a metformina nella classica formulazione in compresse: primi risultati di uno studio clinico 76
Effects of berberine on lipid profile in subjects with low cardiovascular risk 76
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. 76
Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial 76
A role for quercetin in coronavirus disease 2019 (COVID-19) 75
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 75
Rosiglitazone maleate and glimepiride in fixed combination for the metabolic control of type 2 diabetes 75
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 75
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 75
Pharmacotherapy for Obesity 75
Curcumin: A natural pan-HDAC inhibitor in cancer 75
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus 75
Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients 75
Matrix metalloproteinase-2 and – 9 levels in obese patients 74
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients 74
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 74
Current and emerging pharmacotherapies for the management of hypertension, focus on aliskiren 74
Effetti di sitagliptin o metformina associati a pioglitazone in pazienti diabetici scarsamente controllati 74
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients 73
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 73
Evaluation of candesartan compared to olmesartan on insulin sensitivity-related parameters in type 2 diabetic hypertensive patients 73
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 73
Effetto del telmisartan sui marcatori infiammatori a digiuno e postprandiale nei pazienti diabetici ipertesi 73
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 73
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 73
The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus 73
Overview of biochemical markers of bone metabolism. 73
Variation of some inflammatory markers in hypertensive patients after one year of olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies. 72
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials 72
Effects of thiazolidinediones and sulfonylureas in patients with diabetes 71
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 71
Totale 9.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.812
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.812
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.146 0 0 0 0 0 217 8 319 46 286 225 45
2021/20221.031 9 4 65 9 4 6 8 58 59 7 175 627
2022/20233.250 358 193 6 221 372 348 2 198 1.370 40 94 48
2023/20241.058 120 196 37 73 121 257 16 120 9 33 37 39
2024/20253.371 24 329 98 110 70 89 246 284 718 77 368 958
2025/20264.185 552 588 1.066 1.006 817 156 0 0 0 0 0 0
Totale 20.342